Gritstone Oncology to Present Clinical Data from Ongoing GRANITE and SLATE Phase 1 Studies During Investor Webcast on July 13
EMERYVILLE, Calif., June 24, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that the Gritstone management team will host an investor teleconference and webcast on July 13, 2020 at 8:00 a.m. ET to present data from the ongoing Phase 1 studies of its immunotherapy product candidates GRANITE and SLATE. Phase 2 study plans will also be discussed.
Daniel Catenacci, M.D., director of the gastrointestinal oncology program and assistant director of translational research at the Comprehensive Cancer Center in the University of Chicago, will be a featured speaker. He is a principal investigator on both clinical trials.
To participate in the teleconference, please dial (866) 939-3921 (domestic) or (678) 302-3550 (international) and refer to conference ID 4973015. Live audio of the teleconference and accompanying slides will be simultaneously webcast and will be available within the Investors & Media section of the Gritstone Oncology website at https://ir.gritstoneoncology.com/investors/events. An archived replay will be accessible for 30 days following the event.
About Gritstone Oncology